Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Gastroenterol
    November 2025
  1. HINO K, Nishina S, Yanatori I
    Ferroptosis: biology and role in liver disease.
    J Gastroenterol. 2025;60:1339-1361.
    >> Share

  2. TAKEMURA Y, Ueda Y, Takemura R, Mita J, et al
    Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.
    J Gastroenterol. 2025;60:1414-1426.
    >> Share

    October 2025
  3. TAHATA Y, Hikita H, Takaki A, Kurosaki M, et al
    Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.
    J Gastroenterol. 2025 Oct 30. doi: 10.1007/s00535-025-02312.
    >> Share

  4. MAESAKA K, Hikita H, Tahata Y, Nishioka C, et al
    Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Oct 25. doi: 10.1007/s00535-025-02308.
    >> Share

  5. IWASA T, Miwa T, Utakata Y, Oi M, et al
    Development of overt hepatic encephalopathy increases mortality in patients with cirrhosis: a multicenter retrospective cohort study.
    J Gastroenterol. 2025 Oct 17. doi: 10.1007/s00535-025-02309.
    >> Share

  6. NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
    Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.
    J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
    >> Share

  7. MIYAKE T, Yoshida O, Furukawa S, Sato Y, et al
    GPAM upregulation enhances hepatic fat deposition and reduces visceral adipose tissue in response to trans-fatty acids.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02297.
    >> Share

  8. FUJII H, Uchida-Kobayashi S, Kanamori A, Nadatani Y, et al
    Defining optimal fatty liver index thresholds for MASLD and MetALD using controlled attenuation parameter as reference.
    J Gastroenterol. 2025;60:1296-1309.
    >> Share

  9. LEE J, Cha JH, Cho HS, Yang K, et al
    The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study.
    J Gastroenterol. 2025;60:1284-1295.
    >> Share

    August 2025
  10. OHAMA H, Hiraoka A, Tada T, Hirooka M, et al
    Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Aug 20. doi: 10.1007/s00535-025-02290.
    >> Share

  11. KIDO H, Mizukoshi E, Yanagi M, Shihui L, et al
    Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease.
    J Gastroenterol. 2025;60:990-999.
    >> Share

    July 2025
  12. YAMASAKI S, Nakahara T, Tsuge M, Yamaoka K, et al
    Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients.
    J Gastroenterol. 2025 Jul 7. doi: 10.1007/s00535-025-02270.
    >> Share

  13. TSUTSUMI T, Kawaguchi T, Fujii H, Kamada Y, et al
    Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.
    J Gastroenterol. 2025;60:891-904.
    >> Share

  14. SUZUKI T, Matsuura K, Tahata Y, Hikita H, et al
    Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy.
    J Gastroenterol. 2025 Jul 1. doi: 10.1007/s00535-025-02282.
    >> Share

    June 2025
  15. OFUCHI T, Otsu H, Hosoda K, Ikehara T, et al
    VPS45 promotes the progression of hepatocellular carcinoma by recycling beta1 integrin to the cell membrane via the endocytic pathway.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02278.
    >> Share

  16. KAWAGISHI N, Suda G, Tahata Y, Hikita H, et al
    Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02275.
    >> Share

  17. LIU WM, Chen CY, Ma HQ, Zhang QQ, et al
    Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.
    J Gastroenterol. 2025;60:754-769.
    >> Share

    May 2025
  18. ONO A, Hayes CN, Miura R, Kawaoka T, et al
    Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma.
    J Gastroenterol. 2025 May 30. doi: 10.1007/s00535-025-02251.
    >> Share

  19. DING H, Lv H, Sui M, Wang X, et al
    Interaction of neuropilin-1 and hepatocyte growth factor/C-Met pathway in liver fibrosis progression in hepatocyte-specific NRP-1 knockout mice.
    J Gastroenterol. 2025 May 26. doi: 10.1007/s00535-025-02262.
    >> Share

  20. XIA M, Lu Y, Yin F, Cao Z, et al
    The external validation of Dallas Steatosis Index among Asian population: a useful tool for metabolic dysfunction-associated steatotic liver disease identification and prevention.
    J Gastroenterol. 2025;60:621-631.
    >> Share

    April 2025
  21. ZHANG Y, Che N, Wang S, Meng J, et al
    Correction: Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02246.
    >> Share

  22. OURA K, Morishita A, Yano R, Manabe T, et al
    Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.
    J Gastroenterol. 2025 Apr 3. doi: 10.1007/s00535-025-02239.
    >> Share

  23. HANAMATSU H, Suda G, Ohara M, Ogawa K, et al
    Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
    J Gastroenterol. 2025;60:456-468.
    >> Share

    March 2025
  24. MIWA T, Tsuruoka M, Ueda H, Abe T, et al
    Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02232.
    >> Share

  25. AOKI T, Kudo M, Nishida N, Ueshima K, et al
    Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02233.
    >> Share

  26. DU T, Huang Y, Lv Y, Yuan G, et al
    Liver fibrotic burden across the spectrum of hypothyroidism.
    J Gastroenterol. 2025;60:315-327.
    >> Share

  27. WANG H, Liu Z, Fan H, Guo C, et al
    Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD.
    J Gastroenterol. 2025;60:306-314.
    >> Share

    February 2025
  28. NISHIMURA T, Tada T, Akita T, Kondo R, et al
    Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.
    J Gastroenterol. 2025 Feb 24. doi: 10.1007/s00535-025-02224.
    >> Share

  29. TANAKA A, Notohara K, Tobari M, Abe M, et al
    A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
    J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
    >> Share

  30. KOGISO T, Ogasawara Y, Taniai M, Shimada E, et al
    Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease.
    J Gastroenterol. 2025;60:210-221.
    >> Share

  31. KURODA H, Abe T, Kamiyama N, Oguri T, et al
    Novel subharmonic-aided pressure estimation for identifying high-risk esophagogastric varices.
    J Gastroenterol. 2025;60:187-196.
    >> Share

    January 2025
  32. WEN C, Tao H, Chen H, Pu W, et al
    Single-cell RNA sequencing and functional analysis reveal the role of altered glycosylation levels of hepatic macrophages in liver cirrhosis.
    J Gastroenterol. 2025 Jan 31. doi: 10.1007/s00535-025-02218.
    >> Share

  33. ZHANG X, Li J, Yao Y, Zhou M, et al
    Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma.
    J Gastroenterol. 2025 Jan 12. doi: 10.1007/s00535-025-02212.
    >> Share

  34. KASAI Y, Ito T, Masui T, Nagai K, et al
    Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.
    J Gastroenterol. 2025;60:1-9.
    >> Share

    December 2024
  35. ZHANG F, Wang YS, Li SP, Zhao B, et al
    Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study.
    J Gastroenterol. 2024 Dec 23. doi: 10.1007/s00535-024-02202.
    >> Share

  36. MIURA R, Ono A, Nakahara H, Shirane Y, et al
    Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185.
    >> Share

  37. KAMADA Y, Sumida Y, Takahashi H, Fujii H, et al
    Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02179.
    >> Share

  38. IMAI Y, Koizumi Y, Hiasa Y, Hirooka M, et al
    Standard technique in Japan for measuring hepatic venous pressure gradient.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02182.
    >> Share

  39. RABIU L, Zhang P, Afolabi LO, Saliu MA, et al
    Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.
    J Gastroenterol. 2024;59:1053-1078.
    >> Share

    November 2024
  40. CAO Z, Yang Y, Liu S, Sun L, et al
    FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
    >> Share

    October 2024
  41. LIU WJ, Wu WJ, Lin CL, Liu CJ, et al
    Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history.
    J Gastroenterol. 2024 Oct 22. doi: 10.1007/s00535-024-02162.
    >> Share

  42. UENO M, Takeda H, Takai A, Morimura H, et al
    Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Oct 21. doi: 10.1007/s00535-024-02159.
    >> Share

  43. SOMA N, Uchida Y, Kouyama JI, Naiki K, et al
    Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis.
    J Gastroenterol. 2024 Oct 16. doi: 10.1007/s00535-024-02160.
    >> Share

  44. KAWAGUCHI T, Fujishima Y, Wakasugi D, Io F, et al
    Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
    J Gastroenterol. 2024 Oct 11. doi: 10.1007/s00535-024-02158.
    >> Share

  45. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Response to letter to the editor regarding: "Alcohol-associated liver disease increases the risk of muscle reduction and mortality in patients with cirrhosis".
    J Gastroenterol. 2024 Oct 4. doi: 10.1007/s00535-024-02153.
    >> Share

  46. SANCHEZ-MONTEAGUDO A, Ripolles E, Murillo O, Domenech S, et al
    Profile of plasma microRNAs as a potential biomarker of Wilson's disease.
    J Gastroenterol. 2024;59:921-931.
    >> Share

    September 2024
  47. KUNZLER IL, Da Croce MA, Fornari F
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Sep 23. doi: 10.1007/s00535-024-02154.
    >> Share

  48. UENO M, Takeda H, Takai A, Morimura H, et al
    CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Sep 18. doi: 10.1007/s00535-024-02150.
    >> Share

  49. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
    Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
    J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
    >> Share

  50. KAWAGUCHI T, Murotani K, Kajiyama H, Obara H, et al
    Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials.
    J Gastroenterol. 2024;59:836-848.
    >> Share

    August 2024
  51. YU C, Tang Y, Liu M, Xu X, et al
    The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma.
    J Gastroenterol. 2024 Aug 10. doi: 10.1007/s00535-024-02144.
    >> Share

  52. ZHANG Y, Che N, Wang S, Meng J, et al
    Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2024 Aug 3. doi: 10.1007/s00535-024-02140.
    >> Share

    July 2024
  53. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Jul 28. doi: 10.1007/s00535-024-02137.
    >> Share

  54. HAO Y, Hao Z, Zeng X, Lin Y, et al
    Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.
    J Gastroenterol. 2024 Jul 19. doi: 10.1007/s00535-024-02134.
    >> Share

  55. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    >> Share

    June 2024
  56. MIWA T, Utakata Y, Hanai T, Aiba M, et al
    Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance.
    J Gastroenterol. 2024 Jun 11. doi: 10.1007/s00535-024-02126.
    >> Share

  57. WAKABAYASHI SI, Tamaki N, Kimura T, Umemura T, et al
    Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    J Gastroenterol. 2024;59:494-503.
    >> Share

  58. HIROOKA M, Ogawa S, Koizumi Y, Yoshida Y, et al
    iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.
    J Gastroenterol. 2024;59:504-514.
    >> Share

  59. MINO M, Sano A, Kakazu E, Matsubara H, et al
    Differences in branched-chain amino acid to tyrosine ratio (BTR) among etiologies of chronic liver disease progression compared to healthy adults.
    J Gastroenterol. 2024;59:483-493.
    >> Share

    May 2024
  60. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
    ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
    >> Share

    April 2024
  61. FUJIWARA K, Kondo T, Fujimoto K, Yumita S, et al
    Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
    J Gastroenterol. 2024 Apr 7. doi: 10.1007/s00535-024-02097.
    >> Share

  62. CORNEJO-PAREJA I, Amiar MR, Ocana-Wilhelmi L, Soler-Humanes R, et al
    Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
    J Gastroenterol. 2024;59:329-341.
    >> Share

    March 2024
  63. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    >> Share

  64. WANG J, Zhang H, Chen L, Fu K, et al
    CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
    J Gastroenterol. 2024;59:229-249.
    >> Share

    February 2024
  65. WU C, Li J, Jia H, Zhao J, et al
    Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis.
    J Gastroenterol. 2024 Feb 24. doi: 10.1007/s00535-024-02082.
    >> Share

  66. NAMISAKI T, Sato S, Yoshiji H
    Role of combined aerobic and resistance exercise in liver cirrhosis.
    J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
    >> Share

    January 2024
  67. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
    Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
    J Gastroenterol. 2024;59:56-65.
    >> Share

  68. HANAI T, Nishimura K, Unome S, Miwa T, et al
    A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.
    J Gastroenterol. 2024;59:45-55.
    >> Share

    December 2023
  69. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
    Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
    J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
    >> Share

  70. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    >> Share

  71. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    >> Share

    November 2023
  72. YANG Z, Shi M, Liang Y, Zhang F, et al
    Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus.
    J Gastroenterol. 2023 Nov 5. doi: 10.1007/s00535-023-02053.
    >> Share

    October 2023
  73. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    >> Share

  74. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    >> Share

  75. CRANE H, Gofton C, Sharma A, George J, et al
    MAFLD: an optimal framework for understanding liver cancer phenotypes.
    J Gastroenterol. 2023;58:947-964.
    >> Share

    September 2023
  76. KADO A, Tsutsumi T, Yotsuyanagi H, Ikeuchi K, et al
    Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
    J Gastroenterol. 2023 Sep 14. doi: 10.1007/s00535-023-02038.
    >> Share

  77. WEI M, Chen Y, Wang M, Li J, et al
    Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
    >> Share

  78. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    >> Share

  79. LIU C, Zhu S, Zhang J, Wu P, et al
    Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.
    J Gastroenterol. 2023 Sep 4. doi: 10.1007/s00535-023-02040.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016